Inhaled Nitric Oxide for Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension: A Systematic Review and Narrative Synthesis
Neonatology · 2025
DOI: 10.1159/000545034 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Neonatology, 2025. Verfasst von Hiroki Kitaoka und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Nitric Oxide, Bronchopulmonary Dysplasia, Hypertension, Pulmonary, Vasodilator Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Inhaled nitric oxide (iNO) is a selective pulmonary vasodilator. However, its effectiveness in the treatment of bronchopulmonary dysplasia-associated pulmonary hypertension (BPD-PH) and severe BPD remains uncertain. Here we systematically reviewed whether iNO treatment increased or decreased mortality and morbidity among preterm infants with severe BPD or BPD-PH.
Methods
We systematically searched the Ovid MEDLINE, Embase, Cumulative Index to Nursing and Allied Health Literature, Cochrane CENTRAL, and ICHUSHI databases for randomized and non-randomized studies that compared the effects of iNO in patients with severe BPD or BPD-PH. The primary outcome was mortality. Two authors independently screened the articles and extracted the data. A meta-analysis and certainty of evidence assessment using the Cochrane Grading of Recommendations Assessment, Development, and Evaluation criteria were planned.
Results
Among the 1,710 articles, none had a relevant control group and no studies met the eligibility criteria. Using a post hoc analysis, we summarized the ineligible studies that evaluated patients with severe BPD or BPD-PH who received iNO therapy. Although some studies included in the narrative review indicated a decreased pulmonary arterial pressure in patients with severe BPD or BPD-PH at the initiation of iNO therapy, none included a comparator group.
Conclusion
Despite the use of iNO in patients with severe BPD and BPD-PH, no published studies compared the outcomes among patients with BPD treated with versus without iNO. Although some studies without comparator groups reported the effectiveness of iNO in patients with severe BPD and BPD-PH, our results suggest that iNO therapy should be initiated with caution and careful consideration of the target population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
- Department of Pediatrics, The Jikei University School of Medicine, Tokyo, Japan.
- Division of Neonatology, Department of Pediatrics, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
- Department of Health Policy, National Center for Child Health and Development, Tokyo, Japan.
- Division of Neonatology, National Center for Child Health and Development, Tokyo, Japan.
Zitieren
APA
Kitaoka, H., Kobayashi, R., Tanaka, K., Watanabe, M., & Isayama, T. (2025). Inhaled Nitric Oxide for Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension: A Systematic Review and Narrative Synthesis. Neonatology. https://doi.org/10.1159/000545034
Vancouver
Kitaoka H, Kobayashi R, Tanaka K, Watanabe M, Isayama T. Inhaled Nitric Oxide for Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension: A Systematic Review and Narrative Synthesis. Neonatology. 2025. doi:10.1159/000545034
BibTeX
@article{Kitaoka2025,
author = {Kitaoka, Hiroki and Kobayashi, Ryota and Tanaka, Kosuke and Watanabe, Masahiko and Isayama, Tetsuya},
title = {Inhaled Nitric Oxide for Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension: A Systematic Review and Narrative Synthesis},
journal = {Neonatology},
year = {2025},
doi = {10.1159/000545034}
}
EUVIMED